Joris Komen1,2, Tomas Forslund3,4, Paul Hjemdahl4, Morten Andersen1, Björn Wettermark1,3. 1. Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institute, Karolinska University Hospital, T2, SE-171 76, Stockholm, Sweden. 2. Department of Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, the Netherlands. 3. Public Healthcare Services Committee, Department of Healthcare Development, Stockholm County Council, Box 6909, 102 39, Stockholm, Sweden. 4. Department of Medicine Solna, Clinical Epidemiology/Clinical Pharmacology, Karolinska Institutet and Karolinska University Hospital, L7:03, SE-171 76, Stockholm, Sweden.
Abstract
AIMS: The aim of the present study was to assess the effect of policy interventions - i.e. reimbursement decisions, guidelines and regional recommendations - on the prescribing of oral anticoagulant treatment in patients with atrial fibrillation (AF). METHODS: Interrupted time series analyses were carried out using monthly data on all patients with a recorded diagnosis of AF newly initiated (switchers and anticoagulant-naïve patients alike) on warfarin, dabigatran, rivaroxaban or apixaban in the Stockholm region from April 2011 until February 2016. RESULTS: A total of 34 165 initiations in 27 942 patients were included. The publication of the European Guidelines was associated with an increase in novel oral anticoagulant (NOAC) initiations of 12.5% [95% confidence interval (CI) 7.3, 17.7] after 5 months. The choice between the different NOACs was mainly associated with changes in the regional recommendations, with apixaban initiations increasing by 19.5% (95% CI 16.3, 22.7) 5 months after the drug was recommended as a first-line alternative to warfarin. Dabigatran received a second-line recommendation but initiations decreased by -9.5% (95% CI -12.6, -6.4), and initiations of rivaroxaban, which had no specific recommendation, decreased by -9.2% (95% CI -12.7, -5.7). A steady decrease in warfarin and increase in NOAC initiations was seen throughout the study period and from November 2015, AF patients were more likely to receive apixaban than any other anticoagulant, while less than 20% of the initiations were with warfarin. CONCLUSIONS: After reimbursement and inclusion in the European guidelines, the NOACs started gaining in popularity, while changes in regional recommendations were associated with the biggest change in prescribers' choice between the different NOACs.
AIMS: The aim of the present study was to assess the effect of policy interventions - i.e. reimbursement decisions, guidelines and regional recommendations - on the prescribing of oral anticoagulant treatment in patients with atrial fibrillation (AF). METHODS: Interrupted time series analyses were carried out using monthly data on all patients with a recorded diagnosis of AF newly initiated (switchers and anticoagulant-naïve patients alike) on warfarin, dabigatran, rivaroxaban or apixaban in the Stockholm region from April 2011 until February 2016. RESULTS: A total of 34 165 initiations in 27 942 patients were included. The publication of the European Guidelines was associated with an increase in novel oral anticoagulant (NOAC) initiations of 12.5% [95% confidence interval (CI) 7.3, 17.7] after 5 months. The choice between the different NOACs was mainly associated with changes in the regional recommendations, with apixaban initiations increasing by 19.5% (95% CI 16.3, 22.7) 5 months after the drug was recommended as a first-line alternative to warfarin. Dabigatran received a second-line recommendation but initiations decreased by -9.5% (95% CI -12.6, -6.4), and initiations of rivaroxaban, which had no specific recommendation, decreased by -9.2% (95% CI -12.7, -5.7). A steady decrease in warfarin and increase in NOAC initiations was seen throughout the study period and from November 2015, AFpatients were more likely to receive apixaban than any other anticoagulant, while less than 20% of the initiations were with warfarin. CONCLUSIONS: After reimbursement and inclusion in the European guidelines, the NOACs started gaining in popularity, while changes in regional recommendations were associated with the biggest change in prescribers' choice between the different NOACs.
Authors: Anne R Mason; Michael F Drummond; Jane A Hunter; Adrian K Towse; Jonathan Cooke Journal: Appl Health Econ Health Policy Date: 2005 Impact factor: 2.561
Authors: Lars L Gustafsson; Björn Wettermark; Brian Godman; Eva Andersén-Karlsson; Ulf Bergman; Jan Hasselström; Lars-Olof Hensjö; Paul Hjemdahl; Ingrid Jägre; Margaretha Julander; Bo Ringertz; Daniel Schmidt; Susan Sjöberg; Folke Sjöqvist; Carl-Olav Stiller; Elisabeth Törnqvist; Rolf Tryselius; Sigurd Vitols; Christer von Bahr Journal: Basic Clin Pharmacol Toxicol Date: 2011-04 Impact factor: 4.080
Authors: Racquel Jandoc; Andrea M Burden; Muhammad Mamdani; Linda E Lévesque; Suzanne M Cadarette Journal: J Clin Epidemiol Date: 2015-03-11 Impact factor: 6.437
Authors: Anne M Holbrook; Jennifer A Pereira; Renee Labiris; Heather McDonald; James D Douketis; Mark Crowther; Philip S Wells Journal: Arch Intern Med Date: 2005-05-23
Authors: Gregory Y H Lip; Stephen A Mitchell; Xianchen Liu; Larry Z Liu; Hemant Phatak; Sumesh Kachroo; Sarah Batson Journal: Int J Cardiol Date: 2015-11-17 Impact factor: 4.164
Authors: Rickard E Malmström; Brian B Godman; Eduard Diogene; Christoph Baumgärtel; Marion Bennie; Iain Bishop; Anna Brzezinska; Anna Bucsics; Stephen Campbell; Alessandra Ferrario; Alexander E Finlayson; Jurij Fürst; Kristina Garuoliene; Miguel Gomes; Iñaki Gutiérrez-Ibarluzea; Alan Haycox; Krystyna Hviding; Harald Herholz; Mikael Hoffmann; Saira Jan; Jan Jones; Roberta Joppi; Marija Kalaba; Christina Kvalheim; Ott Laius; Irene Langner; Julie Lonsdale; Sven-Äke Lööv; Kamila Malinowska; Laura McCullagh; Ken Paterson; Vanda Markovic-Pekovic; Andrew Martin; Jutta Piessnegger; Gisbert Selke; Catherine Sermet; Steven Simoens; Cankat Tulunay; Dominik Tomek; Luka Vončina; Vera Vlahovic-Palcevski; Janet Wale; Michael Wilcock; Magdalena Wladysiuk; Menno van Woerkom; Corrine Zara; Lars L Gustafsson Journal: Front Pharmacol Date: 2013-05-14 Impact factor: 5.810
Authors: Jaran Eriksen; Lars L Gustafsson; Kristina Ateva; Pia Bastholm-Rahmner; Marie-Louise Ovesjö; Malena Jirlow; Maria Juhasz-Haverinen; Gerd Lärfars; Rickard E Malmström; Björn Wettermark; Eva Andersén-Karlsson Journal: BMJ Open Date: 2017-05-02 Impact factor: 2.692
Authors: Irene Eriksson; Joris Komen; Fredrik Piehl; Rickard E Malmström; Björn Wettermark; Mia von Euler Journal: Eur J Clin Pharmacol Date: 2018-02-10 Impact factor: 2.953
Authors: Marie Bradley; Emily C Welch; Efe Eworuke; David J Graham; Rongmei Zhang; Ting-Ying Huang Journal: J Gen Intern Med Date: 2020-09-28 Impact factor: 5.128